drug

Integrated Care Program (ICP)

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
OTHER
Pre-approval / investigational in the US
Developed by AstraZeneca
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
OTHER

Indications

Trials

1
Schizophrenic Patients in Integrated Care
NCT00681629Phase 4Terminated

KOLs & investigators

1
Martin Lambert, ProfessorKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
AstraZeneca
company
trial
Schizophrenic Patients in Integrated Care
PHASE4
trial
indication
Schizophrenia
indication
Schizophreniform Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Martin Lambert, Professor
KOL score 5
person